Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
November 20, 2015
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Daniel V T Catenacci, Wei-Li Liao, Lei Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 23, 2018
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase
Sarit Schwartz, Chris Szeto, Yuan Tian, et al.
The Lancet. Oncology
|
July 24, 2019
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
Maud Toulmonde, Marina Pulido, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2020
<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor Resistance
Robin Guo, Michael Offin, A Rose Brannon, et al.
Tumori
|
June 12, 2020
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
Maria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T Li, Ronglai Shen, Darren Buonocore, et al.
Nature Medicine
|
May 30, 2018
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Gabrielle S Wong, Jin Zhou, Jie Bin Liu, et al.
Nature Medicine
|
August 11, 2018
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Gabrielle S Wong, Jin Zhou, Jie Bin Liu, et al.
Cancer Discovery
|
November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Cancer Discovery
|
March 28, 2020
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Bob T Li, Flavia Michelini, Sandra Misale, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
November 20, 2015
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Daniel V T Catenacci, Wei-Li Liao, Lei Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 23, 2018
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase
Sarit Schwartz, Chris Szeto, Yuan Tian, et al.
The Lancet. Oncology
|
July 24, 2019
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
Maud Toulmonde, Marina Pulido, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2020
<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor Resistance
Robin Guo, Michael Offin, A Rose Brannon, et al.
Tumori
|
June 12, 2020
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
Maria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T Li, Ronglai Shen, Darren Buonocore, et al.
Nature Medicine
|
May 30, 2018
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Gabrielle S Wong, Jin Zhou, Jie Bin Liu, et al.
Nature Medicine
|
August 11, 2018
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Gabrielle S Wong, Jin Zhou, Jie Bin Liu, et al.
Cancer Discovery
|
November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Cancer Discovery
|
March 28, 2020
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Bob T Li, Flavia Michelini, Sandra Misale, et al.
Page
of 5